10.9 MEAD
Summary
Ozurdex is a biodegradable, sustained-release implant previously approved to treat macular edema related to retinal vein occlusion and to treat noninfectious posterior segment uveitis. MEAD comprised two large, multicenter 3-year clinical trials designed to evaluate dexamethasone 0.7 mg and 0.35 mg to support the regulatory filing.
Quiz Module 10.9
Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account
To validate your answers and keep track of your progress please sign in or register a new account
1. The MEAD study examined the efficacy of which of the following?
2. Patients treated with the dexamethasone implant achieved statistically significant and clinically meaningful visual improvements over 3 years with how many injections?